[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100574795":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":109,"collaborators":24,"id":111,"slug":112,"hasResults":113,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":113,"sex":119,"minAge":120,"maxAge":121,"enrollmentInfo":122,"targetDuration":24,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":134,"whyStopped":24,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":144},{"fullName":5,"class":6},"Fundacion Dexeus","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Subcutaneous Triptorelin","ACTIVE_COMPARATOR","200 mcg subcutaneous triptorelin 34-36 hours prior to planned oocyte collection",[13],"Drug: Subcutaneous Triptorelin",{"label":15,"type":10,"description":16,"interventionNames":17},"Intranasal Nafarelin","800 mcg intranasal nafarelin 36 hours prior to planned oocyte collection",[18],"Drug: Intranasal nafarelin",[20,25],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit.. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.\n\nOnce 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.\n\nn the control group, 200 mcg subcutaneous triptorelin will be administered 34-36 hours prior to planned oocyte collection.",[9],null,{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":24},"Intranasal nafarelin","Women undergoing fertility preservation will undergo progesterone-primed ovarian stimulation according to the standard operating protocol for the clinical unit. For participants taking oral contraceptives before the treatment, the pill-free interval before starting ovarian stimulation will be 5 days. Participants will administer exogenous gonadotropins (recombinant or urinary), along with 200mg oral micronized progesterone per day for pituitary suppression. Participants using any commercially available gonadotropin preparation will be eligible for inclusion.\n\nOnce 3 follicles ≥18mm are observed, participants will be randomised to one of the study arms.In the experimental group, 800 mcg intranasal nafarelin will be administered 34-36 hours prior to planned oocyte collection.",[15],[30],{"name":31,"affiliation":32,"role":33},"Nikolaos P Polyzos, MD, PhD","Dexeus Fertility","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":24,"email":38},"CONTACT","0034932274700","nikpol@dexeus.com",{"name":40,"role":36,"phone":37,"phoneExt":41,"email":42},"Ignacio Rodríguez, MSc","22029","nacrod@dexeus.com",[44,62,75,90,98],{"facility":45,"status":24,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"Dexeus Mujer Sabadell","Sabadell","Barcelona","08203","Spain","ES",{"type":52,"coordinates":53},"Point",[54,55],2.10942,41.54329,{"lat":55,"lon":54},[58,60],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":24},"Silvia Grau, MD",{"name":59,"role":61,"phone":24,"phoneExt":24,"email":24},"SUB_INVESTIGATOR",{"facility":63,"status":24,"city":64,"state":47,"zip":65,"country":49,"countryCode":50,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"Dexeus Mujer Sant Cugat","Sant Cugat del Vallès","08190",{"type":52,"coordinates":67},[68,69],2.08611,41.47063,{"lat":69,"lon":68},[72,73],{"name":59,"role":36,"phone":24,"phoneExt":24,"email":24},{"name":74,"role":33,"phone":24,"phoneExt":24,"email":24},"Silvia Grau",{"facility":76,"status":24,"city":77,"state":78,"zip":79,"country":49,"countryCode":50,"cosmosGeoPoint":80,"geoPoint":84,"contacts":85},"Dexeus Mujer Reus","Reus","Tarragona","43202",{"type":52,"coordinates":81},[82,83],1.10687,41.15612,{"lat":83,"lon":82},[86,88],{"name":87,"role":36,"phone":24,"phoneExt":24,"email":24},"Josep Gonzalo, MD",{"name":89,"role":61,"phone":24,"phoneExt":24,"email":24},"Josep Gonzalo",{"facility":91,"status":24,"city":47,"state":24,"zip":92,"country":49,"countryCode":50,"cosmosGeoPoint":93,"geoPoint":97,"contacts":24},"Departamento de Ginecología Obstetricia y Reproducción. Hospital Universitari Dexeus","08037",{"type":52,"coordinates":94},[95,96],2.15899,41.38879,{"lat":96,"lon":95},{"facility":99,"status":24,"city":78,"state":24,"zip":100,"country":49,"countryCode":50,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Dexeus Mujer Tarragona","43206",{"type":52,"coordinates":102},[103,104],1.24544,41.11905,{"lat":104,"lon":103},[107,108],{"name":87,"role":36,"phone":24,"phoneExt":24,"email":24},{"name":87,"role":61,"phone":24,"phoneExt":24,"email":24},{"type":110,"investigatorFullName":24,"investigatorTitle":24,"investigatorAffiliation":24,"oldNameTitle":24,"oldOrganization":24},"SPONSOR","100574795","phase-4-intranasal-nafarelin-for-triggering-oocyte-maturation-100574795",false,"NCT06763926","Intranasal Nafarelin For Triggering Oocyte Maturation","Intranasal Nafarelin Compared to Subcutaneous Triptorelin for Triggering Final Oocyte Maturation in Ovarian Stimulation: a Non-inferiority Randomised Controlled Clinical Trial","INFORM","Inclusion Criteria:\n\n* Women undergoing fertility preservation cycles with oocyte cryopreservation\n* Undergoing a progesterone-primed ovarian stimulation cycle (PPOS) with any commercially available gonadotropin preparation(s)\n* BMI 18 - 30 kg\u002Fm2\n\nExclusion Criteria:\n\n* Allergy or hypersensitivity to either of the study drugs\n* Hypopituitarism\n* Known pituitary tumour\n* Contraindication to intranasal medication administration\n* Previous poor response to agonist trigger","FEMALE","18 Years","40 Years",{"count":123,"type":124},154,"ESTIMATED","INTERVENTIONAL",[127],"PHASE4","This is a non-inferiority randomised, controlled clinical trial comparing subcutaneous triptorelin to intranasal nafarelin for the final maturation of oocytes in women undergoing fertility preservation cycles with oocyte cryopreservation undergoing ovarian stimulation.",[130],"Fertility Preservation",[132,133],"IVF","GnRH agonist","NOT_YET_RECRUITING","2026-06-02",{"date":137,"type":138},"2026-06-04","ACTUAL",{"date":140,"type":124},"2026-06-15",{"date":142,"type":124},"2028-01-15",{"name":5,"class":6},5]